secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001178913-26-001615
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion gets Israeli MoH approval for Phase 2/3 trial of SIL204 in pancreatic cancer
--------------------------------------------------------------------------------

- SIL204 is a next-generation RNAi therapy targeting multiple KRAS mutations in pancreatic cancer.
- Approval follows positive preclinical anti-tumor data and completed toxicology studies.
- Human trials expected to begin in Q2 2026; also planning German application in current quarter.
- Company plans to pursue additional KRAS-driven indications including colorectal and lung cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326001615/0001178913-26-001615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326001615/zk2634889.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-001615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer